Pfizer (NYSE:PFE) Lifted to “Hold” at DZ Bank
DZ Bank upgraded shares of Pfizer (NYSE:PFE) from a sell rating to a hold rating in a report issued on Wednesday morning, The Fly reports. They currently have $36.00 target price on the biopharmaceutical company’s stock.
Other equities analysts also recently issued research reports about the stock. Morgan Stanley reduced their price objective on shares of Pfizer from $40.00 to $38.00 and set an equal weight rating for the company in a research note on Tuesday. Barclays reissued a hold rating and issued a $41.00 price objective on shares of Pfizer in a research note on Thursday, May 9th. Credit Suisse Group reissued a neutral rating on shares of Pfizer in a research note on Monday, August 12th. JPMorgan Chase & Co. set a $46.00 price objective on shares of Pfizer and gave the stock a neutral rating in a research note on Monday, July 29th. Finally, Goldman Sachs Group reissued a buy rating and issued a $49.00 price objective on shares of Pfizer in a research note on Monday, June 17th. Fifteen equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of Hold and an average price target of $45.88.
Pfizer stock opened at $35.55 on Wednesday. The company has a 50 day moving average price of $38.37 and a 200-day moving average price of $41.17. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.21 and a current ratio of 1.47. Pfizer has a fifty-two week low of $33.97 and a fifty-two week high of $46.47. The company has a market capitalization of $194.03 billion, a PE ratio of 11.43, a P/E/G ratio of 2.80 and a beta of 0.63.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, August 2nd will be given a dividend of $0.36 per share. This represents a $1.44 dividend on an annualized basis and a dividend yield of 4.05%. The ex-dividend date is Thursday, August 1st. Pfizer’s payout ratio is presently 48.00%.
In other news, insider Alexander R. Mackenzie sold 30,000 shares of the company’s stock in a transaction on Thursday, June 20th. The stock was sold at an average price of $44.00, for a total transaction of $1,320,000.00. Following the transaction, the insider now directly owns 80,094 shares of the company’s stock, valued at $3,524,136. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Scott Gottlieb purchased 3,000 shares of Pfizer stock in a transaction dated Friday, August 23rd. The shares were acquired at an average cost of $34.72 per share, for a total transaction of $104,160.00. Following the completion of the transaction, the director now owns 3,000 shares of the company’s stock, valued at approximately $104,160. The disclosure for this purchase can be found here. Corporate insiders own 0.09% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. Evolution Wealth Advisors LLC purchased a new stake in shares of Pfizer during the second quarter valued at $34,000. IMA Wealth Inc. grew its holdings in shares of Pfizer by 144.5% during the second quarter. IMA Wealth Inc. now owns 807 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 477 shares during the last quarter. Winch Advisory Services LLC grew its holdings in shares of Pfizer by 69.6% during the fourth quarter. Winch Advisory Services LLC now owns 819 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 336 shares during the last quarter. Ruggie Capital Group purchased a new stake in shares of Pfizer during the fourth quarter valued at $44,000. Finally, Financial Gravity Wealth Inc. grew its holdings in shares of Pfizer by 33.2% during the second quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 257 shares during the last quarter. 71.58% of the stock is currently owned by hedge funds and other institutional investors.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Story: How to find the components of the quick ratio
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.